92 Upcoming Life Science Events at MaRS for April 5th and 27th 2006

PDAD&C #92, 2005-2006

MEMORANDUM

To: Principals, Deans, Academic Directors and Chairs
From: John R.G. Challis, Vice-President, Research and Associate Provost
Date: March 16, 2006
Re:  

Upcoming Life Science Events at MaRS - April 5th & 27th, 2006



______________________________________________________________________________________

Dear Colleagues,

We would like to make you aware of the following Life Sciences events taking place at the MaRS Centre, 101 College St, Toronto this April. Please forward this email to any colleagues that you believe may find these events of interest.

These events are:

Wednesday, April 5th (9:00AM to 12:45PM)

PRECLINICAL DEVELOPMENT WORKSHOP (MaRS Best Practices Series) Extracting Full Value of Your Basic Research: The move toward drug development.

 

SPACE IS LIMITED AS THIS EVENT IS COMPLIMENTARY. PRE-REGISTRATION IS REQUIRED.

An overview of this event can be found at the bottom of this email.

Thursday, April 27th (11:30AM to 1:00PM)

DRUG DEVELOPMENT DISCUSSION GROUP

First Meeting Topic: Markers in Clinical trials - an entertaining hobby or a key component of the FDA Critical Path initiative?

This technical discussion group is targeted at industry, clinical & academic researchers interested in drug development.

SPACE IS LIMITED AS THIS EVENT IS COMPLIMENTARY. PRE-REGISTRATION IS REQUIRED.

An overview of this event can be found at the bottom of this email.

Upcoming Events Poster

To download a one page pdf document that highlight these two events taking place in April click on the following link.

Please feel free to print and post this information as you desire.

 

Thanks,

Nina Chagnon

MaRS Discovery District

____________________________________________________________________________________

April 5th, 2006 Best Practices Event

Extracting The Full Value Of Your Basic Research: The move toward drug development The genome revolution is driving rapid discovery of novel molecular mechanisms for therapeutic intervention, while advances in engineering and chemistry are yielding new tools and solutions to unmet medical needs. These scientific and technological breakthroughs are creating a keen interest in drug discovery.

What you will learn?

This seminar is intended to give a broad overview of the first steps in drug development after initial discovery.

In this seminar, industry experts will:

  • Outline the general concepts in pre-clinical drug development.
  • Identify the strategies to consider in obtaining Investigational New Drug (IND) status in an effective manner in order to move into clinical trials as soon as possible.
  • Determine what pre-clinical data is needed to attract VC money.
  • Determine what pre-clinical data a biotech looks for before considering in-licensing your technology.
  • Explain how to take a novel drug idea from a research institution bench top and turn it into a start-up biotech.
  • Industry experts will address these topics during the morning session, with time allotted to address questions.

Intended as an introduction survey to pre-clinical drug development, this seminar is designed to be followed by more in depth courses on drug development depending upon demand.

Who should attend?

The seminar is primarily targeted at faculty, postdoctoral fellows, and advanced graduate students in basic science, engineering and clinical departments who may be involved in innovative drug development projects.

Location:

MaRS Centre, 101 College

Time: 9:00 a.m. at 12:15 p.m.

Date: Wednesday, April 5th at 9:00-12:30

Program outline:

9:00 Introductions: Dr Brian Barber, UHN Global Ventures

9:10 Overview of pre-clinical concepts and strategies: Wendy Hill,

Principal Gap Strategies and Dr Isobel Ralston, President Torealis

10:30 Coffee break

10:45 What VCs are looking for in Pre-Clinical data before they will

invest: Dr Luc Marengere, Managing General Partner, Vengrowth

11:15 What Biotechs are looking for in Pre-Clinical data before they will

partner or in-license: Sean Thompson, Director Corporate Development, YM

Bioscience

11:45 Trillium Therapeutics: examples of a successful launch from a

research bench: Dr Niclas Striernholm, CEO Trillium Therapeutics

12:15 Q&A

Drug Development Discussion Group

About the Drug Development Discussion Group

The Drug Development Discussion Group (DDD Group) is an informal moderated forum bringing together research professionals and clinicians interested in drug development.

Think of DDD Group as a Journal Club focused on global drug development issues; a place to hear candid comments from the practitioners in the field, a chance to debate and develop a rapport with industry and academic professionals you do not necessarily deal with on a daily basis.

Format:

  1. The group will meet on the last Thursday of every other month, 11:30am -1pm beginning April 27, 2006
  2. Each session is composed of a 30-minute presentation and a 45-minute moderated discussion.
  3. Prior to the meeting, MaRS will send a background paper/report relevant to the discussion.

Rules of Engagement:

No solicitations

  • No disclosure of confidential information
  • Propose discussion topics and speakers

Send suggestions to vlitinski@marsdd.com

BioMarkers in Clinical trials: an entertaining hobby or a key component of the FDA critical path initiative?

Date: Thursday, April 27, 2006

Time: 11: 30 am to 1pm. Bring your lunch.

Location: MaRS Discovery District, 101 College St, Toronto, ON

Registration: Click here to register or email dddgroup@marsdd.com Registered participants will receive background materials.

Presentation by Ontario Cancer Biomarker Network (OCBN)

Moderator: Brian Barber, UHN Global Ventures

If you are interested in moderating future sessions please contact Veronika Litinski vlitinski@marsdd.com